By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Neuronetics, Inc. 

One Great Valley Parkway
Suite 2
Malvern  Pennsylvania  19355  U.S.A.
Phone: 610-640-4202 Fax: 610-640-4206


Medical Device

Company News
Neuronetics, Inc. Raises $15 Million In Series G Equity Financing, Led By Ascension Ventures 6/6/2017 8:59:51 AM
Neuronetics, Inc. Release: NeuroStar TMS Therapy, A Non-Drug Treatment, Shows Promise As Monotherapy In Treating Women With Postpartum Depression 5/17/2016 9:34:04 AM
Neuronetics, Inc. Release: Depression Patients Who Are Successfully Treated With NeuroStar TMS Therapy May Not Need Antidepressant Medications 3/24/2016 7:31:29 AM
Neuronetics, Inc. Announces Launch Of First Ever Randomized, Controlled Clinical Trial To Evaluate Non-Drug NeuroStar TMS Therapy In Adolescent Patients With Major Depressive Disorder 11/2/2015 6:17:26 AM
Neuronetics, Inc. Appoints Christopher Thatcher As President And Chief Executive Officer 12/3/2014 7:35:22 AM
Neuronetics, Inc. Release: Neurostar TMS Therapy® Shows Promise As Effective Once-Monthly Maintenance Therapy In Patients With Major Depressive Disorder 5/6/2014 9:28:26 AM
Neuronetics, Inc. Release: Data Published in CNS Spectrums Indicate Acute Transcranial Magnetic Stimulation (TMS) With NeuroStar TMS Therapy® Improves Quality of Life in Patients with Depression 9/16/2013 11:03:16 AM
Neuronetics, Inc., Announces First Patients Enrolled in Clinical Trial to Evaluate NeuroStar TMS Therapy in Women with Postpartum Depression 7/30/2013 9:20:36 AM
Neuronetics, Inc. Release: New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients With Depression using NeuroStar TMS Therapy System 5/22/2013 9:41:13 AM
Neuronetics, Inc. Release: NeuroStar TMS Therapy, a Non-Drug Depression Treatment, Demonstrates Statistically Significant Benefits on Patient-Reported Pain Outcomes 3/20/2013 8:51:47 AM